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Abstract
Long Term AMPK Activation Limits Obesity Induced Muscle Atrophy
Joshua C. Drake
The aim of this study was to identify obesity-induced alterations in regulatory
mechanisms of skeletal muscle mass and how they would be altered with long
term (8 weeks) AMPK-agonist treatment. 8 week old male, lean (L) wild type
[body weight (BW) = 26.9 g] and ob/ob (O) [BW = 46.2 g] mice were fed an AMP
kinase (AMPK) activator, β-GPA (F), mixed at a 1% concentration within their
food or normal chow as control (C) for 8 weeks. Following an overnight (12 hr)
fast, all mice were sacrificed and the gastrocnemius complex was excised for
analysis. Muscle mass was lower in the OC mice (121.08 ± 9.3 mg) versus LC
(158.4 ± 5.6 mg). This corresponded with decreases in raptor associated with
mTOR. Following treatment, western analysis of OF muscle lysates displayed
increased AMPK and acetyl-CoA carboxylase phosphorylation compared with LC
and OC mice. OC mice displayed higher activation of mammalian Target of
Rapamycin (mTOR)-regulated signaling (S6K1, 4E-BP1, and GSK3), which was
reciprocally altered after 8 weeks of β-GPA feeding. These data show that long
term (8 week) AMPK-agonist treatment can augment obesity-induced alterations
in regulatory mechanisms of skeletal muscle mass through the normalization to
lean levels of mTOR signaling.
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Chapter 1: Specific Aims and Hypotheses
Introduction to the Problem
Obesity has recently moved to the forefront of health care concerns in the
United States.

Many of the health problems associated with obesity like

lipotoxicity, dyslipidemia, type 2 diabetes and chronic inflammation have
significant impacts on skeletal muscle function.

These decreases in function

impact the activity level, independence, and quality of life of an individual. This
decrease in function is due to muscle atrophy induced by obesity (54). Loss in
muscle mass is due to an imbalance between the protein synthesis and
degradation rates (3). Mammalian Target of Rapamycin (mTOR) increases RNA
translation and protein synthesis initiating growth. As growth is an energetically
expensive process, mTOR responds in the presence of adequate nutrients (4, 5,
41, 68, 84).

Obesity is a state of excessive nutrients and displays elevated

mTOR signaling, however, skeletal muscle atrophy is present (6, 27, 38, 63, 67,
72).

AMP-activated protein kinase (AMPK), a sensor of low energy and

malnutrition, inhibits the mTOR pathway and promotes oxidative metabolism.
While numerous studies have examined AMPK in relation to metabolic
complications during obesity, it remains unclear how therapies activating AMPK
and/or repressing highly activated mTOR will improve obesity-induced muscle
atrophy.

Understanding this dysregulation and how AMPK activation affects

growth signaling will provide insights towards new and innovative ways to treat
and prevent the problem of obesity, resulting in improved quality of life in these
individuals and lower health care costs.
Specific Aims and Hypothesis
The objectives of this study are to: (1) evaluate the effectiveness of AMPK
agonist treatment on skeletal muscle growth and protein formation during
obesity; (2) identify the central regulatory pathway that contributes to muscle
atrophy induced by obesity. The central hypothesis of this study is that
AMPK activation can improve obesity-induced skeletal muscle atrophy by
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augmenting growth signaling.

We will test the central hypothesis and

accomplish the objectives of this study by pursuing the following specific aims:
1. Determine the role of AMPK activation on skeletal muscle mass and
morphology within obese muscle. Our hypothesis is that 8 weeks of βGPA (AMPK agonist) feeding will activate AMPK, increasing total muscle
mass relative to body weight and tibial length by enhancing accretion of
protein in obese skeletal muscle.
2. Determine how obesity alters mTOR-related signaling in skeletal muscle
and evaluate the benefit of AMPK activation.

Our hypothesis is that

activated AMPK will subsequently improve growth related signaling, such as
Akt, by reducing the activation of mTOR substrates S6K1 and 4E-BP1 and
promote proper ratio of mTOR with raptor and eIF4F complex formation in
fasted obese skeletal muscle.
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Chapter 2: Background and Significance
Obesity and Insulin Resistance
Obesity has become a major medical concern in most of the developed
world, particularly, in the United States. The Center for Disease Control and
Prevention (CDC) define obesity as a body mass index (BMI) ≥ 30. Over the
past 20 years the US has seen a significant increase in the amount of the
population that fits this criterion. In 2008, thirty-two states showed a 25% or
greater prevalence of obesity among their populations. Six of those (Alabama,
Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia) showed
that 30% or greater of their population had a BMI of at least 30 (2).
Insulin Resistance
Insulin resistance is commonly associated with excessive weight gain
and/or hyperlipidemia, i.e. obesity (43).

Using the homeostasis model

assessment index (HOMA) and glucose sensitivity index (Si) on obese and lean
subjects showed that the HOMA was 2.3 fold higher in obese compared to the
lean and the Si was 2.1 higher in the lean compared to the obese subjects (57).
Insulin resistance is also associated with an increase in several pancreatic
peptides other than just insulin, such as amylin (an insulin complement that
regulates

glucose

appearance),

glucagon

(important

in

carbohydrate

metabolism), and gastric inhibitory polypeptide (helps induce insulin secretion)
(57).
Glucose uptake into skeletal muscle accounts for approximately 80% of
the total insulin-stimulated glucose disposal (81).

Because of this, skeletal

muscle is heavily linked to the development of the insulin resistance that leads to
type 2 diabetes (39).

The primary means by which glucose enters skeletal

muscle is by the Glut 4 transport protein (39). In obese men and diabetic rats,
Glut 4 has lower expression when compared to lean controls (21, 39). Glut 4
expression is also fiber type-dependent. He et al. (28) proposed that a muscle
fiber’s sensitivity to insulin was dependent on the fiber type with type I being the
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most sensitive, followed by type IIa then IIb. Using Sprague-Dawley rats, at
physiological insulin concentration, red (type I) muscle transports twice as much
glucose as white (type II) muscle (39). From basal insulin concentrations to
maximum concentration, type II skeletal muscle shows only a 6x increase in
glucose transport compared to a 17x increase in type I skeletal muscle fibers
(39). Type I fibers also contain 5.2x more Glut4 mRNA as well as total protein
when compared to type II fibers (39).
Fatty acids
Obese human subjects display significant increases in endogenously
synthesized long-chain fatty acid species C16:0, C16:1, C18:1 (57).

This

increase in the fatty acid pool represents the fatty acids circulating in triglycerides
or other esterified species.

Because of this, obese subjects display higher

triglyceride levels when compared to lean cohorts (57). Increases in circulating
triglycerides are central in the pathogenesis for their accumulation within skeletal
muscle (47, 74), known as intramuscular triglycerides (IMTG). Both in vitro and
in vivo exposure of skeletal muscle to increased lipids, (ex. high fat diet or lipid
infusion) results in an accumulation of IMTG (21, 28, 35, 43, 94).

This

corresponds with the increase in IMTG that is seen within the skeletal muscle of
obese and type 2 diabetic subjects when compared to lean controls (21, 23, 43,
88, 94). There is a fiber type-specific accumulation that occurs in association
with obesity and type 2 diabetes in that IMTG are further elevated in the type I
fibers (23). For example, in soleus muscles (comprised primarily of type I fibers)
of obese adolescent males showed an increase in IMTG (74). An increase in
IMTG depends on several factors: the availability and efficiency of fatty acid
uptake, the rate of fatty acid oxidation, and the rate of synthesis and hydrolysis of
triacylglycerides (94).
A large proportion of fatty acid oxidation, referred to as β-oxidation, occurs
within the skeletal muscle or more specifically within the mitochondria (88).
Regulation of mitochondrial function is believed to be through peroxisome
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proliferators-activated receptor gamma coactivator 1-alpha (PGC-1α) (11).
Cultured myotubes from type 2 diabetic patients display mitochondrial
dysfunction which is believed to be caused by disturbances that occur
downstream of β-oxidation (94). Thus, during increases in fatty acid influx or βoxidation there is corresponding increase in production and release of acid
soluble metabolites that result in the increases in IMTG seen in obesity and type
2 diabetes (94).

When these myotubes from type 2 diabetic patients are

exposed to elevated fatty acids, PGC-1α (a key factor in β-oxidation) gene
expression is increased but the response is blunted (94). PGC-1α coactivator
peroxisome proliferators-activated receptor (PPARγ) and mitochondrial marker
cytochrome c oxidase IV (COXIV) are significantly reduced in the muscles of
raptor (a component of mTOR essential for proper muscular growth) knock out
mice linking its functions to that of muscle growth (4).
Lipolysis is the catabolic reaction that breaks down one molecule of TAG
into three fatty acid molecules (56). When dysregulation of lipolysis of IMTG is
present there is an increase in the amount of diacylglycerides (DAG). Moro et al
(56) compared the hydrolysis of TAG and DAG and found an imbalance that
resulted in a higher rate of TAG hydrolysis compared to DAG hydrolysis, which
caused DAG to accumulate. The dysregulation of lipolysis just mentioned is also
responsible for the creation of new ceramides within the skeletal muscle (56).
Ceramides and DAG are both associated with the lipotoxicity that is found in
obese and type 2 diabetic populations (56, 97), although DAG is believed to be
the most influential of the two.

Ceramides have been shown to not change

following a 5hr lipid infusion (97), however, this could be due to the period of
infusion not being long enough.

Therefore, it is not IMTG themselves that

contribute to insulin resistance but rather impairments in the way they are broken
down.
A high fat diet increases IMTG but it also decreases insulin stimulated
skeletal muscle glucose uptake (58).

The dysregulation of lipolysis through
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increases in circulating free fatty acids and the subsequent accumulation of
IMTG is integral in the pathogenesis of insulin resistance by inhibiting glucose
transport (47, 68). This manifests as a decrease in glucose oxidation and the
synthesis of glycogen within skeletal muscle (68). Intramuscular glucose-6phosphate concentration, whose release is insulin dependent and vital in
glycolysis within the muscle, is lowered below baseline values in nine healthy
human subjects following lipid infusion (68), further suggesting that fatty acids
play an inhibitory role in glucose transport.
Further investigation into the signaling behind insulin resistance shows
that increases in plasma fatty acids inhibit insulin activation of insulin receptor
substrate 1 (IRS-1) associated PI3-kinase at the level of IRS-1 (97). A 30%
reduction in IRS-1 tyrosine phosphorylation and a 50% reduction in IRS-1
associated PI3-kinase activity is observed in rats following 5 hrs of lipid infusion
(97). The reduction in insulin activation of IRS-1 associated PI3-kinase activity
coincides with activation of the enzyme Protein Kinase C that is believed to be
responsible for the inhibition of IRS-1. PKC-θ needs DAG for activation, which is
already elevated during obesity and type 2 diabetes (56, 97) so the role of PKC-θ
in the inhibition of IRS-1 associated PI3-kinase activity is likely.
Obesity and Muscle
Muscle Size
In obesity the mass of the muscle in proportion with body size is reduced,
significantly impacting the function of skeletal muscle.

When comparing 74

obese human subjects (BMI ≥ 30 kg/m2) to 67 lean subjects (BMI < 25 kg/m2),
the obese subjects had twice as much total fat mass as the lean controls, but
only a 17% increase in lean mass (57). This corresponded to 60% of the obese
subjects’ body weight being made up of muscle compared to 71% in the lean
controls (57). This trend is also visible in mice and is specific to the muscle (38).
In ob/ob mice the sternomastoid, extensor digitorum longus (EDL), and soleus
muscles are 30%, 21%, and 13% smaller, respectively, when compared to lean
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controls (38). This corresponded to a muscle mass-to-body mass ratio of -62%
for the sternomastoid, -56% for the EDL, and -52% for the soleus compared to
lean controls. These smaller muscle sizes in obese mice were also associated
with smaller fiber size by examining the cross sectional areas, except in the
soleus where the cross sectional area was similar between ob/ob and lean mice
(38).
Satellite Cells
During normal turnover in skeletal muscle, myofiber nuclei are lost. The
maintenance and replacement of these nuclei is the role of satellite cells.
Satellite cells are normally found between the basal lamina and the sarcolemma
of the myofibrils. Hypertrophy of skeletal muscle depends on proper function of
these satellite cells (62). Obese Zucker rats, an insulin resistant obese model,
show a decrease in the amount of myonuclei compared to lean cohorts,
evidenced by BrdU staining on plantaris and soleus muscle (62). Similar findings
have been seen in the ob/ob mouse. Myofibers in 3-week-old ob/ob mice had
less satellite cell proliferative activity than did lean controls (63).
Muscle Structure
Skeletal muscle is made up of different types of myofibers. The two main
types are the slow-twitch oxidative fiber, Type I, and the fast-twitch glycolytic
fibers, Type IIa, IIx, IIb and IIc (7, 14, 61). Each fiber type has different metabolic
properties.

Type I fibers, for example, have been shown to contain a high

amount of intramuscular lipids, not seen in type II fibers (20, 28, 36, 42). Type I
fibers, which use primarily aerobic metabolism, are better equipped to use lipids
as fuel. It has been shown that the amount of weight loss and reduction in BMI
following gastric bypass surgery in morbidly obese subjects was related with the
amount of type I fibers each subject had (82).
It has been shown in rats, mice, and humans that there is a significant
decrease in the amount of type I fibers associated with obesity (27, 29, 31, 36,
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38, 83, 88). Likewise, there is a significant increase in type II fibers with obesity
(36, 38, 83), particularly type IIb fibers (36, 83). Along with this fiber type shift
there has been found to be an increase in the amount of hybrid fibers in the
sternomastoid, EDL, and the soleus in ob/ob mice compared to lean cohorts (38).
This shift corresponds with the increase in functional demand on the postural
muscles that are now being required to support a larger body mass, locomotor
muscles that are overcoming greater inertia in order to move, and an increase in
the effort behind ventilation (38).
Protein Synthesis and Translation Initiation
Obesity by itself can cause complications with protein synthesis. Mice that
were made obese by goldthioglucose injection showed less adaptive growth
following an exercise regime (3). When compared to lean controls, these obese
mice showed only a 2x increase in protein turnover whereas lean mice show a 3x
increase (3). Protein content is also lower in the muscles of the obese mice
compared to lean cohorts (3).

There is data suggesting that altered protein

synthesis in the obese is slower in slow (type I) muscle more so than fast (type II)
muscle fibers. Protein turnover has been shown to be slowest and total RNA
content lower in type I fibers of the vastus lateralis fibers of dogs, mice, rats, and
fowl (75).
Muscle growth is dependent upon the synthesis of proteins through the
initiation of polypeptide chains. Protein synthesis within skeletal muscle is
controlled by hormonal and nutritional factors as well as the body’s supply of
amino acids, insulin and other initiation factors, RNA, and met-tRNA (64). Insulin
does not necessarily stimulate protein synthesis but rather facilitates synthesis by
stimulating downstream machinery (79).

For example, for the initiation of

peptide-chains to take place within eukaryotic cells there must be an mRNA
dependent binding of the 40S and 60S ribosomal subunits creating an 80S
monomer (64). The binding of mRNA to the 40S ribosomal subunit involves the
binding of eIF-4E (eukaryotic initiation factor – 4E) to the m7GTP cap at the
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5’end of the mRNA. The newly formed eIF-4E – mRNA complex binds to another
initiation factor, eIF-4G, which contains binding sites for the other initiation
factors, eIF-4A and eIF-3. This complex then binds to the 40S ribosomal subunit
(78). Phosphorylation of 4E-BP1 is caused by insulin and IGF-1 (79). 4E-BP1
also regulates 40S ribosome binding to mRNA, though indirectly, by increasing
the availability of eIF-4E (78). When eIF-4E is bound to 4E-BP1 it can bind to
mRNA through the m7GTP cap but not to eIF-4G. But when 4E-BP1 is
phosphorylated it releases eIF-4E allowing it to bind with eIF-4G and
subsequently to the 40S ribosomal subunit (78).
Impaired insulin and IGF-1 action, like in obesity and diabetes, leads to
atrophy of skeletal muscle due to its inability to synthesize proteins (37, 57). In
the db/db diabetic mouse model, there is a 48% decrease in protein synthesis
when compared to lean controls (72).

The accompanying decrease in RNA

negatively affects translational efficiency not allowing the formation of new
peptide chains (64).

RNA concentrations in gastrocnemius muscles of male

Sprague-Dawley rats were 13% lower after just two days in a simulated diabetic
state (25). Since approximately 80% of RNA is rRNA, any decreases in RNA will
blunt protein synthesis (25).
Amino Acids
Part of the action of insulin on protein synthesis is its effects on stimulating
the incorporation of amino acids into proteins (78). Increases in the amounts of
circulating amino acids are observed in obesity (57). Branched chain amino
acids have been shown to affect carbohydrate metabolism by decreasing the
glucose used within skeletal muscle (60). In obese humans, eight amino acids
have

been

shown

leucine/isoleucine,

to

be

significantly

phenylalanine,

increased

tyrosine,

(alanine,

valine,

glutamate/glutamine,

aspartate/asparagines, and arginine) compared to lean cohorts (57). This could
cause a build up in these amino acids because they compete for transport with
the large neutral amino acid transporter, LAT1, resulting in the reduced
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production of neurotransmitters (i.e. serotonin) and catecholamines within the
central nervous system (57). Since IGF-1 is decreased in obesity, combined with
overnutrition, the larger amounts of circulating amino acids will be diverted into
catabolic pathways instead of being used for protein synthesis. For example,
glutamate increases in α-ketoacids, C5, and C3 acylcarnitines. C5 acylcarnitines
are comprised of subunits that lead to mitochondrial isoleucine and leucine
catabolism (57). High glutamate could also increase transamination of pyruvate
to alanine (both found to be increased in obesity), which could lead to glucose
intolerance in obesity (57).
Growth Signaling
Mammalian Target of Rapamycin (mTOR)
Rapamycin is used in clinical applications, such as organ transplants and
cancer treatment, because of its immunosuppressive action that negatively
affects proliferation. The molecular target of rapamycin is a Ser/Thr kinase called
mTOR in mammals (86). mTOR is a part of the phosphatidyl-inositol 3 kinase
(PI3K) family of enzymes (67).

mTOR is associated with sensing nutrient

availability, adjustment of insulin action in vivo, increases in muscle mass via an
increase in RNA translation and protein synthesis, the balance of ATP
production, and regulating mitochondrial function (4, 5, 44, 71, 92). mTOR is
comprised of two separate multiprotein complexes, mTOR Complex 1 (TORC1)
and mTOR Complex 2 (TORC2) (34, 69).

TORC1 consists of the regulatory

protein of mTOR, raptor, which is rapamycin-sensitive (4, 41). Raptor interacts
with IRS-1 to regulate the phosphorylation of IRS-1 at Ser-636/639 by mTOR
(89). TORC1 controls the phosphorylation of downstream targets 4E-BP1 and
ribosomal protein S6 kinase-1 (S6K1) (16). When mTOR phosphorylates 4EBP1, eIF-4E is free to bind with other initiation factors and the 40S ribosomal
subunit, allowing translation initiation to occur. S6K1 activation causes feedback
inhibition

of

the

insulin/IGF1

pathway

by

decreasing

the

levels

and

phosphorylation of IRS-1 (26, 90). However, this effect on IRS-1 phosphorylation
is not direct. This is done through another negative feedback regulation of PI3-
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kinase/Akt signaling by phosphorylating rapamycin-sensitive residues such as
Ser307 (89). Another protein in TORC1 is mLST8, which interacts directly with
mTOR and positively regulates its ability to phosphorylate S6K1 (89).
In muscle cells glucose uptake is controlled through activation of the PI3kinase/Akt pathway, which is stimulated by insulin (59).

When TORC1 is

activated for prolonged periods of time, as is the case in nutrient excess, insulin
resistance results due to decreased signal transduction of insulin at the level of
IRS-1 (54, 67, 85). Consequently, ribosomes released following peptide-chain
termination accumulate as 80S monomers, not as 40S and 60S subunits (37).
This has detrimental effects on translation initiation. Insulin resistance associated
with increased TORC1 is evidenced in the ob/ob mouse, which has constantly
activated TORC1 associated with increases in basal PKB/Akt activity (54).
Raptor knock out mice (RAmKO) show significant decreases in S6K1 and
4E-BP1 phosphorylation and display progressive muscular dystrophy (4).
Glycogen content is increased in the EDL, soleus, and gastrocnemius muscles of
these animals (4).

EDL and soleus muscles in RAmKO mice also display

significant decreases in oxidative enzymes, intermyofibrillar mitochondria, and
glucose uptake from the blood (4). This provides further evidence of the role of
the complex in controlling muscle mass, oxidative metabolism, and insulin action.
TORC2 consists of Rictor, which is the rapamycin-insensitive component
of mTOR (4). TORC2 controls the phosphorylation of PKB/Akt at Ser473 (70).
PKB/Akt acts as a feedback regulator of TORC1 activation (6) and is acted on by
S6K1 to regulate IRS-1 phosphorylation through negative feedback (89).
PKB/Akt increases TORC1 by phosphorylating TSC 1 and 2 (54). This enhances
GTP loading to Rheb, an mTOR interacting protein that is essential for mTOR
activity (54). In order for phosphorylation of Akt at Ser 473 to take place the
rictor interacting protein mSin1 is required (89). A downstream target of PKB/Akt
is glycogen synthase kinase 3α/β (GSK3α/β). The β isoform of GSK3 has been
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shown to be the major enzyme that inhibits glycogen synthase (33, 52). When
phosphorylated by Akt, GSK3β is inhibited, increasing glycogen synthase activity
(52).
The rictor knock out mouse (RImKO) appears normal and does not die
prematurely like RAmKO mice (4). There is no change in the structural makeup
of the EDL and Soleus muscles that is responsible for the absence of muscular
dystrophy (4). Interestingly, there is a slight decrease in the amount of raptor in
the RImKO mice (4). PKB/Akt on Ser 473 is still phosphorylated, meaning that
mTORC2 is not required for its phosphorylation (4) but apparently it plays a role
in the degree of raptor expression.
AMPK
AMPK operates in response to stress as a cellular fuel sensor particularly
as a result of the AMP:ATP ratio (12, 24). AMPK is a ubiquitous Ser/Thr kinase
heterotrimer made up of a catalytic α subunit as well as β and γ regulatory
components that complete the complex (35, 48). The most common causes of
AMPK activation are hypoglycemia, exercise, and fasting (35). When activated,
it initiates the production of ATP while inhibiting pathways that consume it (48).
In skeletal muscle, AMPK regulates glucose metabolism and gluconeogenesis
(66). It also controls fatty acid oxidation by phosphorylating acetyl-CoA
carboxylase 2 (ACC2) (66). Situations where lipid metabolism is impaired, as in
obesity, could be a result of a dysregulation in the fuel sensing ability of AMPK
(35).

If fatty acids cannot be oxidized within the mitochondria they will be

synthesized into DAG, ceramides, and TG within the cytosol causing inhibition of
the insulin pathway decreasing glucose uptake (35). 3-guanidinopropionic acid
(β-GPA) is a known AMPK activator by competing against phosphocreatine and
not allowing it to enter into the muscle and subsequently lowing ATP levels (18,
19, 73). β-GPA has been shown to induce hypoglycemia in non-diabetic rabbits
(1).

Its effects on reducing glucose and insulin levels as well as increasing

insulin sensitivity have been seen in ob/ob mice (53).
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5’-aminoimidazole-4-

carboxamide-1-β-D-ribofuranoside (AICAR) is another known AMPK activator
(10, 12, 67).

AICAR acts as an intermediate in the generation of inosine

monophosphate (IMP), an AMPK agonist, thus increasing activity of AMPK (10,
12, 67). Exercise also affects AMPK by depleting ATP and increasing amounts
of AMP. This change in the AMP:ATP ratio increases AMPK activity.
AMPK’s control of mTOR
AMPK controls translation and growth via an mTOR dependent
mechanism. Increases in AMP activate AMPK by phosphorylating the Thr 172
residue on the catalytic α subunit (35). AMPK in turn causes the phosphorylation
and subsequent inactivation of acetyl-CoA carboxylase (ACC), the rate-limiting
enzyme in fatty acid oxidation (83). ACC has two isoforms, ACC1 and ACC2,
with ACC2 being the predominant isoform within skeletal muscle.

AMPK

phosphorylates ACC1 on Ser 79 and ACC2 on the equivalent Ser 221 repressing
the mTOR pathway (23, 83). This decreases fatty acid production as well as upregulates fatty acid oxidation and mitochondrial biogenesis by increasing citrate
synthase and succinate dehydrogenase (23, 35, 66, 67, 77).
AMPK phosphorylates the tuberous sclerosis complex 2 gene product,
Tuberin or TSC2 (92).

TSC2, whose function is inhibited upstream by Akt,

functions as a GTPase-activating protein (GAP) to the Rheb G protein, an
upstream target of mTOR (13). Rheb is then converted to its inactive GDP form
that decreases mTOR activity (13).

Therefore, AMPK also acts indirectly to

inhibit mTOR signaling through TSC2.
Fatty Acids
Chronic exposure to lipids increases mTORC 1 and 2 formation (67).
Increases in mTORC1 were indicated by increased activation of S6K1 at Thr 389
(67). This increased the serine phosphorylation of IRS-1 (67).

mTORC2

formation was coupled with increases in Akt at Ser 473 (67). Increases in fatty
acids have also been associated with suppressed AMPK signaling (76).
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Significance
Considering the rising prevalence of obesity among the population of this
country, understanding the effects that obesity has on skeletal muscle mass will
be crucial for combating this problem. Because of the role skeletal muscle plays
in substrate utilization, basal metabolic rate, functionality, and personal
independence, any detriments in size and function of the muscle has significant
impacts on both quality of life and the financial burden of health care. As our
obese population grows older, there will be factors contributing that are
detrimental to skeletal muscle.

Having an understanding of skeletal muscle

mass in the role of obesity alone plays will improve care in individuals. Findings
from this study will point towards new ways to treat and prevent the problem of
obesity, thus improving the quality of life in these individuals.
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Chapter 3: Methods
Aim #1: Determine the role of AMPK activation on skeletal muscle mass
and morphology within obese muscle.
Design
The experimental groups consisted of 8 C57BL/6 (lean) mice and 8 ob/ob
mice fed either a 1% β-GPA containing diet, or 8 lean and ob/ob mice fed normal
chow. Ob/ob mice are a rodent model of obesity and hyperlipidemia. These
mice spontaneously develop a mutation of the leptin gene and subsequently
develop high circulating levels of triglycerides, total cholesterol, and low density
lipoproteins (15, 32). The ob/ob mouse also displays characteristics of type 2
diabetes in that hyperinsulinemia, hyperglycemia, insulin resistance, hyperaminoacidemia, and intolerance to glucose are all present (9, 15, 49-51). Few
studies have examined skeletal muscle growth regulation in these animals or
how to attenuate their muscle loss. The data show lower activation of the insulin
stimulated PI 3-kinase/Akt growth pathway and that mTOR signaling is highly
active in these animals (54, 98). This makes them a good experimental model to
gain insight into the intricacies of how these pathways control muscular growth
during obesity but also to discover an efficient means by which to treat these
pathologies.
Feeding with 1% β-GPA is being used as a means to increase AMPK
activation. This quantity of β-GPA was chosen based on the viability and
response of the animals in previous experiments using the same diet (17-19, 73).
Body weight and food intake were recorded twice a week for the duration of the
8-week feeding. The experimental period is ample time to observe changes in
skeletal muscle mass relative to body weight and tibial length (75, 87). The
average weight of the mice in each cage as well as food intake was calculated
each week. Following a 12 hr fast, muscle was collected while the animal was
anesthetized. Gastrocnemius complexes were weighed then immediately frozen
in liquid nitrogen. Tibial lengths were measured as another means to normalize
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muscle growth.

We measured the ATP in muscle and examined AMPK

activation as validation of the treatment.
Aim #2: Determine how obesity alters mTOR-related signaling in skeletal
muscle and evaluate the benefit of AMPK activation.
Design
The experimental groups consisted of 8 C57BL/6 (lean) mice, 8 ob/ob
mice fed a 1% β-GPA containing diet, and 8 lean and ob/ob mice fed normal
chow.

1% β-GPA was used as a means to increase AMPK activation and

repress mTOR signaling. This quantity of β-GPA is based on the viability and
response of animals in previous experiments using the same diet (17-19, 73).
The goal was to identify the regulatory pathway through which AMPK activation
attenuates obesity-induced muscle atrophy. The experimental period was ample
time to observe changes in skeletal muscle mass relative to body weight and
tibial length. Body weight and food intake were measured 2x week throughout
the feeding period. After the proposed period, muscle samples were collected
while the animal is under anesthesia. The gastrocnemius complex was analyzed
by immunoprecipitation and Western Blot for mTOR and mTOR-related activation
and association.
General Methodologies
Animals – Lean and ob/ob (Catalog #000632) male mice from Jackson
Laboratories in Bar Harbor, ME were used for the proposed experiments. All
animals were maintained on a 12:12, light:dark cycle and controls were fed
standard chow (Harlan; #2018) while the experimental groups are fed β-GPA
(Sigma-Aldrich; #G 6878) mixed with standard chow (Harlan; #2018).

The

experimental diet was prepared by Harlan. The experimental groups consisted
of 8 C57BL/6 (lean) mice fed β-GPA, 8 ob/ob mice fed β-GPA, and 8 lean and
ob/ob mice fed normal chow. Food and water was available ad libitum. After the
proposed time and following an overnight fast, samples were collected while the
animal was anesthetized by 4% isoflurane. Body weight was measured while the
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animal was anesthetized.

Gastrocnemius complexes were removed and

weighed then immediately frozen in liquid nitrogen for later analysis. The right
tibia was removed and immediately placed in a -20°C freezer until the length
could be measured.
β-GPA – 3-guanidinopropionic acid was mixed with normal chow from Harlan to
make a 1% β-GPA mixture (17-19, 73). Body weight was measured every 3rd
day (2x week).

Food intake was measured at those times to track food

consumption. The average weight and food intake, per mouse of each cage was
calculated at the end of each week to track body weight gain and food
consumption.
Muscle Size – The gastrocnemius complex (soleus, plantaris, and the two heads
of the gastroc) was surgically dissected tendon-to-tendon and any fat around the
tissue was removed before the muscle was weighed. Because of the likelihood
that body mass change is accompanied by a change in muscle mass, muscle
mass was normalized to body weight, skeletal muscle protein concentration, and
tibia length.
ATP Determination –Invitrogen Detection Technologies ATP Determination Kit
(A22066) was used.

This is a bioluminescence assay for quantitative

determination of ATP with recombinant firefly luciferase and its substrate Dluciferin. Amount of ATP was calculated in the experimental samples from a
provided standard curve.
Homogenizing of Muscle – Muscle tissue was homogenized in 10x homogenizing
buffer.

Homogenizing buffer consisted of 10 µl/ml protease inhibitor, 1 µl/ml

DTT, 5 µl/ml Benzamidine, 2.5 µl/ml Sodium Vanadate, and the rest was made
up of CHAPS buffer. A 50 µl aliquot of the total homogenate was placed in a
separate tube with 50 µl of sample buffer for totally lysate analysis. The
remaining homogenates were spun at 1000xG for 10 min @ 4 °C.
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The

supernatant was taken and placed in separate tubes and the remaining pellet will
be discarded. An aliquot of 10 µl was taken of the samples for a protein assay
while the rest was stored in an -80 °C freezer.
Protein Determination – Bovine serum albumin was used to determine protein
concentration of the muscle samples using the Coommassie Stain Assay
(Thermo Scientific). The plate was run through the plate reader (595 nm) to
calculate protein concentration.

A workable dilution was calculated for each

sample that was used in subsequent Western Blot analysis.
Immunoprecipitation – The sample was processed in CHAPS buffer and 500 µg
of 1000xg supernatant was combined with eIF-4E or mTOR antibody and mixed
overnight. Immune complexes were isolated with a goat anti-rabbit or –mouse
BioMag IgG beads (Qaigen), using a magnetic stand. Precipitates were eluted in
SDS sample buffer, boiled, pelleted by magnet, collected, and subjected to
standard Western analysis for eIF-4E, eIF-4G, and 4E-BP1 (eIF-4E IPs only) or
mTOR and raptor (mTOR IPs only). mTOR’s association with raptor was
analyzed from mTOR immunoprecipitates, and eIF-4E and 4E-BP1 associated
with eIF-4E was examined in eIF-4E immunoprecipitates.
Western Analysis – Degree of activation of AMPK, mTOR and their substrates
raptor, S6K1 (total and phospho), 4E-BP1 (total and phospho), rpS6, eEF-2,
GSK3-α/β, p-Akt (Ser 473 and Thr 308), total Akt, and ACC were analyzed by
Western analysis from skeletal muscle homogenates. Results were normalized
to β-Tubulin. TOR, raptor, S6K1 (total/phospho), GSK3α/β, and ACC were run
on a 7% gel. BP1 (total/phospho), eEF-2, and p-Akt (Ser473/Thr 308), and total
Akt were run on a 4-12% gel. AMPK (phospho), PGC-1α, COXIV, β-Tubulin, and
rpS6 (phospho) were run on a 12% gel. Equal protein was resolved by SDSPAGE (NuPAGE; Invitrogen). A kaleidoscope marker was used to visually
determine protein placement based on weight (kDa). Gels ran for ~90 minutes at
125 V in cold room until samples have run the length of the gel. They were
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transferred to PVDF membrane for 75 min at 30 V. The resulting membranes
were blocked in 5% milk (5 grams dehydrated milk/100 ml TBST) for 60 min at
room temperature. Membranes were rinsed 4x10 minutes with 1x TBST and then
incubated with the appropriate primary antibody diluted in 1x TBST overnight in
cold room. The next day membranes were rinsed 3x5min with 1x TBST then
rocked in their respective HRP-conjugated-secondary antibodies diluted in 5%
milk in TBST. All primary and secondary antibodies were purchased through Cell
Signaling Technology Inc.

Immunoblots were visualized via ECL or ECL-
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and

captured

a

camera-integrated

system

(SynGene).

Concentration of protein expression was assessed by ImageJ software. Results
will then be compared to percent of the control.
Statistics
All data are expressed as mean±standard error of the mean. Comparisons are
made to the lean controls, using a one- or two-way (body weight and food intake
only) ANOVA analysis (Prism v3.0 software; GraphPad Software). The
significance level is P<0.05.
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Chapter 4: Manuscript in JAP style
Abstract
The aim of this study was to identify obesity-induced alterations in regulatory
mechanisms of skeletal muscle mass and how they would be altered with long
term (8 weeks) AMPK-agonist treatment. 8 week old male, lean (L) wild type
[body weight (BW) = 26.9 g] and ob/ob (O) [BW = 46.2 g] mice were fed an AMP
kinase (AMPK) activator, β-GPA (F), mixed at a 1% concentration within their
food or normal chow as control (C) for 8 weeks. Following an overnight (12 hr)
fast, all mice were sacrificed and the gastrocnemius complex was excised for
analysis. Muscle mass was lower in the OC mice (121.08 ± 9.3 mg) versus LC
(158.4 ± 5.6 mg). This corresponded with decreases in raptor associated with
mTOR. Following treatment, western analysis of OF muscle lysates displayed
increased AMPK and acetyl-CoA carboxylase phosphorylation compared with LC
and OC mice. OC mice displayed higher activation of mammalian Target of
Rapamycin (mTOR)-regulated signaling (S6K1, 4E-BP1, and GSK3), which was
reciprocally altered after 8 weeks of β-GPA feeding. These data show that long
term (8 week) AMPK-agonist treatment can augment obesity-induced alterations
in regulatory mechanisms of skeletal muscle mass through the normalization to
lean levels of mTOR signaling.
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Introduction
Many of the health problems associated with obesity like lipotoxicity,
dyslipidemia, type 2 diabetes and chronic inflammation have significant impacts
on skeletal muscle function. This decrease in function is due to muscle atrophy
as seen in both humans and animals (38, 39, 54, 57). Obese humans have been
shown to have as much as twice the amount of fat mass as their lean
counterparts but only 17% more lean mass (58). This corresponds to only 60%
of the body weight in obese subjects coming from skeletal muscle compared to
71% in lean counterparts (58).
Loss in muscle mass is caused by an imbalance between the protein
synthesis and degradation rates (3). Synthesis of protein relies upon ribosomal
mRNA translation that is controlled by the molecular target of rapamycin in
mammals, or mTOR (5, 92).

Acute increases in mTOR result in muscle

hypertrophy and growth but chronically elevated mTOR signaling, as seen in
obese muscle, may negatively impact growth (40, 54, 90).
mTOR is comprised of two separate multi-protein complexes, mTOR
complex 1 and 2, that contain the regulatory proteins raptor and rictor,
respectively (4, 35, 42, 70). Raptor phosphorylates the eukaryotic initiation factor
(eIF) 4E binding protein-1 (4E-BP1) and ribosomal protein S6 Kinase-1 (S6K1)
(8). In its unphosphorylated state, 4E-BP1 binds to eIF-4E, a key initiation factor
in translation, which keeps other initiation factors from binding. Under normal
conditions 4E-BP1 is phosphorylated by raptor, which then releases eIF-4E,
allowing it to bind to eIF-4G and MAP kinase-interacting kinase to form the eIF4F complex (78, 79). The eIF-4F complex then binds with the mRNA and 40S
ribosomal subunit so that together with a 60S subunit a functional 80S
monosome can form (78). S6K1 phosphorylation recruits other proteins involved
in the translation initiation process such as eIF-4B, ribosomal protein S6 (rpS6)
and eukaryotic elongation factor 2 kinase (eEF-2) (16, 65).
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mTOR can be regulated by a ubiquitous Ser/Thr kinase heterotrimer, 5’
AMP-activated protein kinase (AMPK) (36, 53).

Increases in AMP, activates

AMPK by phosphorylating the Thr 172 residue on the catalytic α subunit initiating
ATP production and inhibiting pathways that consume it (36, 53). AMPK
activation causes the phosphorylation and subsequent inactivation of acetyl-CoA
carboxylase (ACC), the rate-limiting enzyme in fatty acid oxidation (89). The two
isoforms of ACC are phosphorylated by AMPK on Ser 79 (ACC1) and Ser 221
(ACC2) repressing the mTOR pathway (23, 89).

This decreases fatty acid

production as well as up-regulates fatty acid oxidation and mitochondrial
biogenesis by increasing citrate synthase and succinate dehydrogenase (23, 36,
67, 68).

AMPK also indirectly regulates mTOR by phosphorylating tuberous

sclerosis complex 2 (TSC2) (94). TSC2 functions as a GTPase-activating protein
(GAP) to the Rheb G protein, an upstream target of mTOR (13). Rheb is then
converted to its inactive GDP form, decreasing mTOR activity (13).
A state of nutrient excess, i.e. obesity, results in chronically elevated
mTORC1 and 2 levels and ultimately insulin resistance (55, 68). In ob/ob mice, a
model of obesity and insulin resistance, it has been shown that there is an
accompanied decrease in AMPK signaling (79).

However, It is unclear how

obese skeletal muscle can display reductions in mass while having excessive
nutrients available and increased mTOR signaling. AMPK’s control of mTOR
and the evidence that it is reduced in obesity make it a desirable target in which
to treat altered mTOR signaling in obese skeletal muscle (13, 23, 83, 96).
Therefore, our goal in this study is to evaluate the effectiveness of long-term
AMPK agonist treatment on skeletal muscle mass during obesity.

Our

hypothesis is that long-term (8 week) treatment with the AMPK agonist, β-GPA,
will normalize obesity-induced increases in mTOR and mTOR-related signaling
to lean levels, promoting proper growth of obese skeletal muscle.
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Materials and Methods
Materials – β-GPA (3-guanidinopropionic acid) was purchased from SigmaAldrich (#G6878) and mixed with normal chow from Harlan (#2018) to make a
1% β-GPA mixture (17-19, 73). ATP Determination Kit (A22066) was purchased
from Invitrogen Detection Technologies. All antibodies were purchased from Cell
Signaling Technology. Anti-mouse horseradish peroxidase-conjugated IgG were
purchased from Cell Signaling Technology. Biomag beads were purchased from
Qaigen.
Animals – Lean and ob/ob (#000632) male mice from Jackson Laboratories in
Bar Harbor, ME were used for the proposed experiments. All animals were
maintained on a 12:12, light:dark cycle and controls were fed standard chow
(Harlan; #2018) while the experimental groups are fed β-GPA (Sigma-Aldrich; #G
6878) mixed with standard chow (Harlan; #2018). The experimental diet was
prepared by Harlan. The experimental groups consisted of 8 C57BL/6 (lean)
mice fed β-GPA, 8 ob/ob mice fed β-GPA, and 8 lean and ob/ob mice fed normal
chow. Food and water were available ad libitum. After the proposed time and
following an overnight fast, samples were collected while the animal was
anesthetized by 4% isoflurane. Body weight was measured while the animal was
anesthetized.

Gastrocnemius complexes were removed and weighted then

immediately frozen in liquid nitrogen for later analysis.

The right tibia was

removed and immediately placed in a -20 °C freezer until the length could be
measured.
β-GPA – 3-guanidinopropionic acid was acquired from Sigma-Aldrich (#G 6878)
and mixed with normal chow from Harlan (#2018) to make a 1% β-GPA mixture
(17-19, 73). Body weight was measured every 3rd day (2x week). Food intake
was measured at those times to track food consumption. The average mouse
and food weight of each cage was calculated at the end of each week to track
body weight gain and food consumption, repetitively.
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Muscle Size – The gastrocnemius complex (soleus, plantaris, and the two heads
of the gastroc) was surgically dissected tendon-to-tendon and any fat around the
tissue was removed before the muscle was weighed. Because of the likelihood
that body mass change is accompanied by a change in muscle mass, muscle
mass was normalized to body weight, skeletal muscle protein concentration, and
tibia length.
ATP Determination – We used Invitrogen Detection Technologies’ ATP
Determination Kit (A22066). This is a bioluminescence assay for quantitative
determination of ATP with recombinant firefly luciferase and its substrate Dluciferin. Amount of ATP was calculated in the experimental samples from a
provided standard curve.
Homogenizing of Muscle – At a later time muscles tissue were homogenized in
10x homogenizing buffer. Homogenizing buffer consisted of 10 µl/ml protease
inhibitor, 1 µl/ml DTT, 5 µl/ml Benzamidine, 2.5 µl/ml Sodium Vanadate, and the
rest was made up of CHAPS buffer. A 50 µl aliquot of the total homogenate was
placed in a separate tube with 50 µl of sample buffer for totally lysate analysis.
The remaining homogenates were spun at 1000xG for 10min @ 4 °C.

The

supernatant was taken and placed in separate tubes and the remaining pellet will
be discarded. An aliquot of 10 µl was taken of the samples for a protein assay
while the rest was stored in an -80 °C freezer.
Protein Determination – A Bovine serum albumin was used to determine protein
concentration of the muscle samples using the Commassie Stain Assay (Thermo
Scientific). The plate was run through the plate reader (595 nm) to calculate
protein concentration. A workable dilution was calculated for each sample that
was used in subsequent Western Blot analysis.
Immunoprecipitation – The sample was processed in CHAPS buffer and 500 µg
of 1000xg supernatant was combined with eIF-4E or mTOR antibody and mixed
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overnight. Immune complexes were isolated with a goat anti-rabbit or –mouse
BioMag IgG beads (Qaigen), using a magnetic stand. Precipitates were eluted in
SDS sample buffer, boiled, pelleted by magnet, collected, and subjected to
standard Western analysis for eIF-4E, eIF-4G, and 4E-BP1 (eIF-4E IPs only) or
mTOR and raptor (mTOR IPs only). mTOR’s association with raptor was
analyzed from mTOR immunoprecipitates, and eIF-4E and 4E-BP1 associated
with eIF-4E was examined in eIF-4E immunoprecipitates.
Western Analysis – Degree of activation of AMPK, mTOR and their substrates
raptor, S6K1 (total and phospho), 4E-BP1 (total and phospho), rpS6, eEF-2,
GSK3-α/β, p-Akt (Ser 473 and Thr 308), total Akt, and ACC were analyzed by
Western analysis from skeletal muscle homogenates. Results were normalized
to β-Tubulin. TOR, raptor, S6K1 (total/phospho), GSK3α/β, and ACC were run
on a 7% gel. BP1 (total/phospho), eEF-2, and p-Akt (Ser473/Thr 308), and total
Akt were run on a 4-12% gel. AMPK (phospho), PGC-1α, COXIV, β-Tubulin, and
rpS6 (phospho) were run on a 12% gel. Equal protein was resolved by SDSPAGE (NuPAGE; Invitrogen). A kaleidoscope marker was used to visually
determine protein placement based on weight (kDa). Gels ran for ~90 minutes at
125 V in cold room until samples have run the length of the gel. They were
transferred to PVDF membrane for 75 minutes at 30 V. The resulting membranes
were blocked in 5% milk (5 grams dehydrated milk/100 ml TBST) for 60 min at
room temperature. Membranes were rinsed 4x10 minutes with 1x TBST, then
incubated with the appropriate primary antibody diluted in 1x TBST over night in
cold room. The next day membranes were rinsed 3x5 min with 1x TBST then
rocked in their respective HRP-conjugated-secondary antibodies diluted in 5%
milk in TBST. All primary and secondary antibodies were purchased through Cell
Signaling Technology Inc.

Immunoblots were visualized via ECL or ECL-
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(SynGene).

Concentration of protein expression was assessed by ImageJ software. Results
will then be compared to percent of the control.
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Statistics
All data are expressed as mean±standard error of the mean. Comparisons are
made to the lean controls, using a one- or two-way (body weight and food intake
only) ANOVA analysis (Prism v3.0 software; GraphPad Software). The
significance level is P<0.05.
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Results
mTOR Signaling Activation in Ob/ob Mouse Skeletal Muscle. Previous studies
(40, 54, 90) have reported that obese mouse models have elevated mTOR
signaling under fasted conditions. In support of our model, we examined mTOR
signaling activation of TORC1 substrates S6K1 and rpS6 in various skeletal
muscles of the lower limb from both lean and ob/ob mice (Fig 1). We examined
predominantly mixed, slow, and fast contractile-type muscles (gastrocnemius,
soleus, and tibialis anterior respectively).

All three muscles types displayed

elevated mTOR signaling under fasted conditions compared to muscles from
lean counterparts.
AMPK and ACC Phosphorylation. Following a 12 hr fast, activation of AMP
Kinase (AMPK), on the phosphorylation site T172 and its substrate acetyl-CoA
carboxylase (ACC) on the S79 phosphorylation site was determined by western
blot analysis to verify the efficacy of the obese model and the treatment with the
AMPK agonist β-GPA. Unlike previous investigations, including our own, there
was no statistically significant difference between the levels of AMPK T172 and
ACC S79 phosphorylation in OC mice to LC mice (Fig 2a). Following 8 weeks of
feeding with β-GPA mixed chow and a 12hr fast, the fasted obese skeletal
muscle AMPK phosphorylation increased significantly above those of the LC
mice. ACC phosphorylation levels significantly increased compared to the OC
mice (Fig 2a).
ATP. ATP was found to be significantly less in the skeletal muscle of both lean
and ob/ob groups fed 1% β-GPA, compared to their respective control groups
(Fig 2b). Since β-GPA is a known creatine kinase competitor, driving down ATP
levels, this data is a positive indicator, along with increased AMPK (p), of the
efficacy of our treatment.
Body Mass and Food Intake Between Groups. Body mass was measured in
each mouse 2x a week. Comparisons were made using a Two Way ANOVA
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analysis.

LF and OC mice displayed significant differences in body mass

throughout the 8 weeks of feeding with the means for LF and OC mice being
42.1% lighter and 86.3% heavier, respectively, than that of LC mice (Table 1).
The OF mice decreased in weight to the point of there being no significant
difference to the weight of the LC mice during week 4 (Fig 3). This reduction in
weight remained until week 6 where the OF mice started to regain weight (~5 g).
However, despite this gain they remained 29.0% lighter than the OC mice and
only 32.3% heavier than LC mice (Table 1) after 8 weeks on the 1% β-GPA.
Food intake between groups also increased in the LC, LF, and OC groups (Fig
4). The OF group ate the least for the first 4 weeks then their intake increased to
where it was similar with LC mice by 8 weeks. This corresponds with the OF
mice having no significant difference in body weight to the LC mice during weeks
4-6 then significantly increased weight gain for the last 2 weeks of the study.
Gastrocnemius Complex Muscle Characteristics. The gastrocnemius complex
(including the soleus, plantaris, and the medial and lateral heads of the
gastrocnemius muscles) skeletal muscle weight was significantly lower in the OC
mice compared to the LC group (Table 1). We then compared muscle weight
relative to body mass and found that this resulted in a ratio that was 59.0% lower
than that of LC (Table 1).

After 8 weeks of β-GPA feeding, the OF group’s

gastrocnemius complex muscle weight was 43.3% lower than that of the LC mice
(Table 1) and significantly less than OC (Table 1). However, relative to body
mass, this resulted in an increase of 5.3% over OC mice (Table 1).
Tibial length was measured in each group. Though statistical significance
was found in both treated groups, it should be noted that there is very little
variance between groups (Table 1). One mouse in the OF group was excluded
from analysis because the tibia was more than two standard deviations away
from the mean. When comparing muscle weight to tibial length the ratio between
the LF and OF groups was 39.8% and 23.5% lower than LC mice, respectively
(Table 1).
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PGC-1α and COX IV.

Western analysis of total muscle lysates for PGC-1α

protein expression, a strong indicator of oxidative metabolism, showed no
difference between lean and ob/ob control mice (Fig 5a). Following 8 weeks of
1% β-GPA feeding there was no change in either lean or ob/ob mice(Fig 5a).
COXIV, an indicator of mitochondrial function, was analyzed via western analysis
of total muscle lysates. Again, no difference was found between lean and ob/ob
control mice or experimental groups (Fig 5b).
Translational Initiation Complex.

Proper formation of the translation initiation

complex is crucial for accruing of muscle mass. Therefore, after 8 weeks of 1%
β-GPA fed conditions, translation initiation complex (i.e. eIF-4F) formation was
examined in eIF-4E immunoprecipitates from lean and obese (ob/ob)
gastrocnemius complex muscle lysates. eIF-4G association with eIF-4E showed
no difference between lean and ob/ob mice regardless of treatment (Fig 6). Total
4E-BP1 associated with eIF-4E showed an increasing trend with 1% β-GPA
feeding in both lean and ob/ob mice but statistical significance was not reached
in either group (Fig 6).
TORC1 Signaling. The mammalian Target of Rapamycin (mTOR) protein is a
major regulator of cell size by complexing and activating several components of
mRNA translation initiation and elongation. TORC1 complex of mTOR contains
the rapamycin-sensitive protein raptor, which binds to mTOR to activate TORC1
substrates.

After 8 weeks of β-GPA fed conditions, raptor was examined in

mTOR immunoprecipitates from lean and obese (ob/ob) gastrocnemius complex
muscles. Raptor associated with mTOR was lower in OC mice compared to LC
(Fig 7).
Analysis of TORC1 downstream targets 4E-BP1, S6K1, and its substrate
ribosomal protein S6 (rpS6) was also conducted by western blot in total cell
lysates.

Following 8 week β-GPA feeding and under fasted conditions, the
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activation of the eIF4E binding protein, 4E-BP1, was significantly higher in the LF
and OF groups compared to Lean mice (Fig 8a). Total 4E-BP1 showed the
same trend though there was no statistical significance found.
The T389 phosphorylation site of S6K1 was lower in OF mice versus OC
mice returning its activation to lean levels (Fig 8b). No significant difference was
found in total S6K1 or rpS6 on the S240/244 phosphorylation site. A substrate of
S6K1, eukaryotic elongation factor (eEF) 2, regulates elongation during mRNA
translation. We analyzed eEF-2 on the T56 phosphorylation site where it was
found to not differ between LC and OC groups (Fig 8c).
TORC2 Signaling. PKB, otherwise known as Akt, is a downstream target of the
rapamycin insensitive component of mTOR, rictor, at the S473 phosphorylation
site. After 8 weeks of β-GPA fed conditions, total Akt and the phosphorylation
sites, T308 and S473 were found to be not significantly different between groups
in fasted skeletal muscle (Fig 9a).

A downstream target of Akt, GSK3, is

inhibited by Akt phosphorylation. GSK3-β isoform is responsible for inhibiting
glycogen synthase (53). GSK3-β was analyzed in fasted skeletal muscle after 8
weeks of β-GPA fed conditions. GSK3-β phosphorylation was found to be
significantly decreased in the OF group compared to OC (Fig 9b).
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Discussion
Many of the health problems associated with obesity, such as, lipotoxicity,
dyslipidemia, type 2 diabetes, and chronic inflammation, have significant
negative impacts on skeletal muscle function. This decrease in function is due to
muscle atrophy induced by obesity (54). Loss of muscle mass is a result of an
imbalance between the rates of protein synthesis and degradation (3).

The

mammalian Target of Rapamycin, mTOR responds in the presence of adequate
nutrients to increase RNA translation and protein synthesis, initiating the growth
process (4, 5, 41, 68, 84). However, in obesity, despite excess nutrients and
elevated mTOR signaling, atrophy remains (6, 27, 38, 63, 67, 72). Therefore, the
goal of this study was to determine if continuous, long term (8 week) feeding with
chow mixed with the AMPK agonist-mTOR antagonist, β-GPA, would normalize
mTOR signaling and mTOR-related processes (i.e. growth) in obese mouse
skeletal muscle to that of lean mice. The results of the present study show that
long term β-GPA feeding to ob/ob mice can normalize aspects of hyperactive
mTOR-related signaling.

This attenuation of mTOR signaling following the 8

week feeding in the obese skeletal muscle can account for some of the
improvement seen in gastrocnemius muscle and total body mass. Therefore,
these data show that feeding ob/ob mice a 1% β-GPA mixed diet (AMPK agonist)
for 8 weeks helps normalize regulatory processes controlling muscle mass. Thus
creating a more positive anabolic environment for the muscle that is sensitive
and capable to growth stimuli.
Our aim in using the well established AMPK agonist, β-GPA, was to
counter the harmful side effects that obesity has on skeletal muscle. Skeletal
muscle that displays dyslipidemia, type 2 diabetes, and/or obesity has been
shown to be less responsive to growth stimuli (40, 54, 90). β-GPA decreases
muscle creatine levels (17, 73) by acting as a competitor. ATP is then broken
down creating higher levels of AMP, subsequently increasing AMPK activation
(17, 95).

Correspondingly, in the current study, 8 weeks of β-GPA feeding

increased AMPK (p) T172 and its substrate, ACC (p) T79, in lean and ob/ob mice
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(Fig 2). Therefore, β-GPA feeding is an effective means by which to improve
obese skeletal metabolism and growth related signaling.

Though previously

known to be an AMPK agonist (17-19, 73, 95), to our knowledge this is the first
study to use β-GPA to promote growth in obese skeletal muscle.
Reduced skeletal muscle size has been associated with obesity in animals
(38, 39) and humans (57), despite an up-regulation of the growth-promoting
mTOR pathway (6, 27, 38, 63, 67, 72), which these data corroborate (Table 1
and Fig 8 & 9). However, skeletal muscle mass in relation with body mass
increased in the β-GPA fed ob/ob mice by 5.7% (versus ob/ob control mice),
however, this change did not reach significance (Table 1). Given that the half-life
of mixed mouse muscle is ~21 days (75, 87) and the dramatic reductions in body
mass that were observed in the β-GPA fed ob/ob mice over the 8 week feeding
period (Table 1), a greater increase in muscle mass was anticipated. Ob/ob mice
fed β-GPA did not differ significantly in body weight from lean control mice
between 4-6 weeks of feeding (Table 1). After which, their food intake increased
and they began to regain weight (Table 1). It is possible that had we examined
muscle weight between 4-6 weeks as opposed to 8 weeks, we would have seen
a larger muscle mass to body mass ratio.
Previous research in obese skeletal muscle has focused on understanding
the metabolic state of the muscle, such as hyperinsulinemia, hyperglycmia,
insulin sensitivity, glucose disposal, dyslipidemia, and glycogen metabolism (25,
28, 40, 58, 82, 88, 94, 96). In the current study we examined several indicators
of metabolic function within the skeletal muscle of obese mice. The current data
show that AMPK (p) T72 was elevated in ob/ob mice after 8 weeks of feeding
with of β-GPA, which regulates glucose metabolism and gluconeogenesis (66).
The rate limiting enzyme in fatty acid oxidation, ACC (p) T79 (83), was also
elevated in the β-GPA fed ob/ob mice. This suggests that 8 weeks of β-GPA
feeding in ob/ob mice increases the efficiency of energy utilization within these
animals. β-GPA fed ob/ob mice showed a 22.5 and 24% increase in PGC-1α and
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COX IV, respectively, compared to control ob/ob mice (Fig 5). PGC-1α and COX
IV are good indicators of oxidative metabolism and mitochondrial function,
respectively (11, 93). Together, these data suggest that 8 weeks of β-GPA
feeding improves the metabolic function of skeletal muscle in ob/ob mice.
The increased potential for growth in ob/ob mice in the current study
comes from the changes in mTOR signaling as a result of β-GPA feeding.
Though no changes in raptor associated with mTOR were seen (Fig 7), there
were alterations in the downstream machinery of mTORC1 signaling. S6K1 (p)
T389 was reduced to levels equivalent to those of the lean control mice (Fig 8b).
S6K1 is used as an indicator of mTORC1 activity and is shown to be elevated in
ob/ob mice (54). Rivas et al. – 2009 showed that following a high fat diet, S6K1
was elevated by 20% at T389 and this increase was totally reversed following
exercise training (i.e. AMPK activation) (67).

Elevated S6K1 results in an

increase in IRS-1 phosphorylation through negative feedback, decreasing insulin
sensitivity and ultimately giving rise to insulin resistance in chronic situations
(67). In mice that are S6K1 deficient, there is a protective effect against obesity
and insulin resistance because of an upregulation in oxidative phosphorylation
and insulin sensitivity (90). Therefore, its lower activation seen after 8 weeks of
β-GPA in ob/ob mice in the current study is suggestive of more normalized
mTOR signaling and some protective effect against insulin resistance.
Interestingly, another mTORC1 substrate, 4E-BP1, was significantly
increased in ob/ob mice fed β-GPA. 4E-BP1 regulates 40S ribosome binding to
mRNA by increasing the availability of eIF-4E (78).

When 4E-BP1 is

phosphorylated it releases eIF-4E allowing it to bind with eIF-4G and
subsequently to the 40S ribosomal subunit (78). A rise in 4E-BP1 was seen in
our previous data after 2 weeks of injections with the AMPK kinase activator
AICAR. It is unclear at this time what role an increase in 4E-BP1 after treatment
with an AMPK kinase activator means.

One thought is that 4E-BP1 acts to

protect against excessive fat deposition and insulin resistance. Le Bacquer et al
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showed that in 4E-BP1 and 4E-BP2 double knock out (DKO) mice gained
significantly more body mass as well as fat mass than their wild type
counterparts (46). When a high fat diet was fed to these DKO mice, insulin
resistance was promoted to a greater extent than in the wild type mice (46). It
could be that the increase in 4E-BP1 that we observed is a protective measure to
guard against the ob/ob mice regaining the fat mass that they had lost in regards
to the β-GPA feeding. In DKO mice, S6K1 phosphorylation was significantly
increased, suggesting that, though both are downstream of mTORC1, and may
have a role in influencing each other (46). Our current data are supportive of this
thought given the reciprocal changes in 4E-BP1 and S6K1 with β-GPA treatment.
We also examined 4E-BP1 within the eIF-4F complex in hopes of
determining what role it plays in obese skeletal muscle. No significant changes
occurred in eIF-4G or 4E-BP1 within the 4F complex following 8 weeks of feeding
with β-GPA in ob/ob mice (Fig 6).

Though 4E-BP1 is phosphorylated by

mTORC1, it is not the only signaling pathway that influences 4E-BP1. Protein
kinase Cδ (PKCδ) and the Erk pathway have also been shown to phosphorylate
4E-BP1 (30, 45). Insulin has also been shown to regulate the phosphorylation of
4E-BP1 through the phosphitidylinositol 3-kinase (PI 3-kinase) signaling pathway,
which is dependent on the phosphorylation and activation of protein kinase B
(PKB)/Akt (22, 80, 91). Had we analyzed skeletal muscle under fed conditions,
we may have observed lower 4E-BP1 in our eIF-4E IPs, providing an alternative
perspective to our treatment. However, determining the exact role 4E-BP1 plays
in obese skeletal muscle remains unclear at this time.
The other binding component of mTOR, rictor, is rapamycin insensitive.
TORC2 controls the phosphorylation of PKB/Akt (70) that acts as a negative
feedback regulator of TORC1 activation (6). In the current data, there were no
significant changes in Akt found in ob/ob mice after 8 the week β-GPA feeding.
Rictor knock out (RImKO) mice function normally but display slight decreases in
the amount of raptor (4). In these RImKO mice Akt is still phosphorylated on Ser
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473 so TORC2 is not solely responsible for Akt phosphorylation. Also, Akt is
hypothesized to play a role in the degree of raptor expression (4). No change in
Akt in the current study could account for the lack of change seen in raptor’s
association with mTOR. However, the downstream target of Akt, GSK3β, which
inhibits glycogen synthase (33, 52), was significantly reduced in ob/ob mice after
β-GPA feeding. Since Akt was unchanged following β-GPA feeding in ob/ob
mice in the current study, there could be another controller of GSK3 activity.
S6K1 has been shown to regulate GSK3 upon the loss of TSC1-2 (99) in vitro,
but more work needs to be done to determine any association in vivo between
the two.
In conclusion, 8 weeks of β-GPA feeding caused decreases in body mass
in ob/ob mice, which was accompanied by a slight increase in skeletal muscle
mass. The obese mouse muscle was more metabolically active following β-GPA
feeding, evidenced by elevated AMPK (p) T72 and ACC (p) S79 levels. β-GPA
feeding did return certain downstream targets of mTORC 1 and 2 signaling
(S6K1 (p) T389 and GSK3) to a level that is comparative with that of their lean
counterparts, which exerts a potential protective effect against regaining fat
mass. Taken together, it is feasible that β-GPA feeding returns ob/ob skeletal
muscle to a state in which growth can be attained under the proper stimulus (i.e.
exercise or nutrition), not unlike their lean counterparts.
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Table 1

Body Weight Muscle

Tibial Length ATP

18.7 ± 0.1

12.0 ± 0.5 *

24.7 ± 1.1

2.1± 0.2 *

5.2 ± 0.2

5.1 ± 0.2

5.0± 0.3 *†

6.6 ± 0.5 *

5.1± 0.2 *

8.5± 0.3

MW/TL

158.5 ± 5.6

18.1 ± 0.2 *

23.4 ± 2.0

2.2 ± 0.2 *

MW/BW

31.29 ± 0.56

92.4 ± 3.6 *

18.5 ± 0.1

8.8 ± 0.5 *

(µM/g Wet wt.)

LC
18.13 ± 1.15*

121.1 ± 9.3*

17.8 ± 0.1 *†

(mm)

LF
58.29 ± 0.63*

89.9 ± 6.0*†

Weight (mg)

OC
41.39 ± 2.31*†

(g)

OF
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Figure Legends
Figure 1.

Fasted mTOR signaling in lean and ob/ob skeletal muscles.

Equal protein from lean and ob/ob male mice gastrocnemius, soleus, and tibialis
anterior muscle homogenates were analyzed by Western blot methods for S6K1
T389 and rpS6 S240/244 phosphorylation sites and normalized to GAPDH.
LC=lean control, OC=ob/ob control. Representative Western blots are shown.
Figure 2.

Long term (8 wk) β-GPA feeding increases fasted AMPK

signaling in ob/ob gastrocnemius muscle. Following 8 weeks of feeding with
1% β-GPA mixed chow, equal protein from lean and ob/ob male mice
gastrocnemius muscle homogenates were analyzed by Western blot methods for
AMPK T172 and ACC S79 phosphorylation sites and normalized to β-Tubulin
(expressed as a percent of LC). LC=lean control, LF=β-GPA fed diet, OC=ob/ob
control, OF=β-GPA fed diet. Representative Western blots are shown. P < 0.05
(n=8 per group, except OC n=7 in p-AMPK, 1 mouse was removed because it
was more than 2 standard deviations from the mean).
Figure 3. Long term (8 wk) β-GPA feeding decreases ATP levels in ob/ob
gastrocnemius muscle. Bioluminescence assay for quantitative determination
of ATP with recombinant firefly luciferase and its substrate D-luciferin. Amount of
ATP was calculated in the experimental samples from a provided standard curve.
Comparisons made using Two-way ANOVA with Bonferroni statistical analysis to
LC. LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.
P < 0.05 (n=8 per group)
Figure 4. Long term (8 wk) β-GPA feeding attenuates weight gain in lean
and ob/ob mice. During 8 weeks of feeding with 1% β-GPA mixed chow body
weight was measured twice weekly as well as post feeding before sacrificing.
Data shows mean weight per treatment plus standard error of the mean.
Comparisons made using Two-way ANOVA with Bonferroni statistical analysis to
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LC. LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet.
P < 0.05 versus LC (n=8 per group).
Figure 5. Food intake during (8 wk) β-GPA feeding between lean and ob/ob
groups. Mean weight of food from each cage eaten at weeks 2, 4, 6.5, and 7.5
are shown with standard error of the mean. Comparisons made using Two-way
ANOVA with Bonferroni statistical analysis to LC. LC=lean control, LF=β-GPA fed
diet, OC=ob/ob control, OF=β-GPA fed diet. P < 0.05 versus LC (n=8 per group).
Figure 6. Long term (8 wk) β-GPA feeding does not change PGC-1α
activation in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle
homogenates were analyzed by Western blot methods for PGC-1α and
normalized to β-Tubulin.

The results are expressed as a percentage of LC.

Percent difference of LF to LC and OF to OC is shown. Representative Western
blots are shown. Comparisons made using One-way ANOVA with Tukey’s
statistical analysis. LC=lean control, LF=β-GPA fed diet, OC=ob/ob control,
OF=β-GPA fed diet. P < 0.05 versus LC (n=8 per group).
Figure 7. Long term (8 wk) β-GPA feeding does not change COXIV
activation in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle
homogenates were analyzed by Western blot methods for COX IV and
normalized to β-Tubulin. The results are expressed as a percentage of LC.
Percent difference of LF to LC and OF to OC is shown. Representative Western
blots are shown. Comparisons made using One-way ANOVA with Tukey’s
statistical analysis. LC=lean control, LF=β-GPA fed diet, OC=ob/ob control,
OF=β-GPA fed diet. P < 0.05 versus LC (n=8 per group).
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Figure 8. Long term (8 wk) β-GPA feeding does not alter eIF-4F complex
formation in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle
homogenates was immunoprecipitated with an eIF-4E antibody, as described in
Methods, and the immunoprecipitates (IP) were assessed for eIF-4G, 4E-BP1,
and eIF-4E content by immunoblot (WB) analysis, and the ratio of eIF-4G to eIF4E and 4E-BP1 to eIF4E was calculated.

The results are expressed as a

percentage of LC. Representative Western blots are shown. Comparisons made
using One-way ANOVA with Tukey’s statistical analysis. LC=lean control, LF=βGPA fed diet, OC=ob/ob control, OF=β-GPA fed diet. P < 0.05 versus LC (n=8
per group).
Figure 9. Long term (8 wk) β-GPA feeding does not change raptor’s
association with mTOR in ob/ob mice. Following 8 weeks of feeding with 1%
β-GPA mixed chow, equal protein from lean and ob/ob male mice gastrocnemius
muscle homogenates was immunoprecipitated with an mTOR antibody, as
described in Methods, and the immunoprecipitates (IP) were assessed for raptor
and mTOR content by immunoblot (WB) analysis, and the ratio of raptor to
mTOR was calculated.

The results are expressed as a percentage of LC.

Representative Western blots are shown. Comparisons made using One-way
ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-GPA fed diet,
OC=ob/ob control, OF=β-GPA fed diet. P < 0.05 versus LC (n=8 per group).
Figure 10. Long term (8 wk) β-GPA increases phosphorylated 4E-BP1 in
ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed chow, equal
protein from lean and ob/ob male mice gastrocnemius muscle homogenates
were analyzed by Western blot methods for 4E-BP1 (p), 4E-BP1 total, and
normalized to β-Tubulin.

The results are expressed as a percentage of LC.

Representative Western blots are shown. Comparisons made using One-way
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ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-GPA fed diet,
OC=ob/ob control, OF=β-GPA fed diet. P < 0.05 versus LC (n=8 per group).
Figure 11. Long term (8 wk) β-GPA decreases phosphorylated S6K1 in
ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed chow, equal
protein from lean and ob/ob male mice gastrocnemius muscle homogenates
were analyzed by Western blot methods for S6K1 T389, S6K1 total, rpS6
S240/244, and normalized to β-Tubulin.

The results are expressed as a

percentage of LC. Representative Western blots are shown. Comparisons made
using One-way ANOVA with Tukey’s statistical analysis. LC=lean control, LF=βGPA fed diet, OC=ob/ob control, OF=β-GPA fed diet. P < 0.05 versus LC (n=8
per group, except OC group in S6K1 T389 and rpS6 S240/244 n=7 because one
mouse was more than two standard deviations away from the mean).
Figure 12. Long term (8 wk) β-GPA does not change eEF-2 in ob/ob mice.
Following 8 weeks of feeding with 1% β-GPA mixed chow, equal protein from
lean and ob/ob male mice gastrocnemius muscle homogenates were analyzed
by Western blot methods for eEF-2 and normalized to β-Tubulin. The results are
expressed as a percentage of LC. Representative Western blots are shown.
Comparisons made using One-way ANOVA with Tukey’s statistical analysis.
LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet. P <
0.05 versus LC (n=8 per group).
Figure 13. Long term (8 wk) 1% β-GPA feeding does not change Akt
signaling in ob/ob mice. Following 8 weeks of feeding with 1% β-GPA mixed
chow, equal protein from lean and ob/ob male mice gastrocnemius muscle
homogenates were analyzed by Western blot methods for Akt T308, Akt S473,
Akt total, and normalized to β-Tubulin.

The results are expressed as a

percentage of LC. Representative Western blots are shown. Comparisons made
using One-way ANOVA with Tukey’s statistical analysis. LC=lean control, LF=β-
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GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet. P < 0.05 versus LC (n=8
per group, except OC group in Akt T308 and S473 n=7 because one mouse was
more than two standard deviations away from the mean).
Figure 14. Long term (8 wk) 1% β-GPA decreases GSK3β in ob/ob mice.
Following 8 weeks of feeding with 1% β-GPA mixed chow, equal protein from
lean and ob/ob male mice gastrocnemius muscle homogenates were analyzed
by Western blot methods for GSK3β and normalized to β-Tubulin. The results
are expressed as a percentage of LC. Representative Western blots are shown.
Comparisons made using One-way ANOVA with Tukey’s statistical analysis.
LC=lean control, LF=β-GPA fed diet, OC=ob/ob control, OF=β-GPA fed diet. P <
0.05 versus LC (n=8 per group, except OC group n=7 because one mouse was
more than two standard deviations away from the mean).
Figure 15. Proposed model of growth signaling in obese skeletal muscle
following long term (8 wk) 1% β-GPA feeding.
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Chapter 5: Discussion of Findings
Specific Aim 1:
Our aim in using the well established AMPK agonist, β-GPA, was to
counter the harmful side effects that obesity has on skeletal muscle. Skeletal
muscle that displays dyslipidemia, type 2 diabetes, and/or obesity has been
shown to be less responsive to growth stimuli (40, 54, 90). β-GPA decreases
muscle creatine levels (17, 73) by acting as a competitor. ATP is then broken
down creating higher levels of AMP, subsequently increasing AMPK activation
(17, 95). Correspondingly, in the current study, 8 weeks of β-GPA feeding
decreased ATP levels and increased AMPK (p) T172 and its substrate, ACC (p)
T79, in lean and ob/ob mice (Fig 2a & b). Though previously known to be an
AMPK agonist (17-19, 73, 95), to our knowledge this is the first study to use βGPA to promote growth in obese skeletal muscle.
Reduced skeletal muscle size has been associated with obesity in animals
(38, 39) and humans (57), despite an up-regulation of the growth-promoting
mTOR pathway (6, 27, 38, 63, 67, 72), which these data corroborate (Table 1
and Fig 8 & 9). However, skeletal muscle mass in relation with body mass
increased in the β-GPA fed ob/ob mice by 5.7% (versus ob/ob control mice),
however, this change did not reach significance (Table 1). Given that the half-life
of mixed mouse muscle is ~21 days (75, 87) and the dramatic reductions in body
mass observed in the β-GPA fed ob/ob mice over the 8 week feeding period
(Table 1), a greater increase in muscle mass was anticipated. Muscle mass was
also compared to tibial length for each animal (Table 1). Muscle mass to tibial
length was similar to the body weight comparisons in that no statistical
significance was found. Ob/ob mice fed β-GPA did not differ significantly in body
weight from lean control mice between 4-6 weeks of feeding (Fig 3). After which,
their food intake increased and they began to regain weight (Fig 3 & Fig 4). It is
possible that had we examined muscle weight between 4-6 weeks as opposed to
8 weeks we would have seen a larger muscle mass to body mass ratio since the
OF group gained weight after 6 weeks of feeding.
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Food intake was particularly difficult to control for the duration of the study.
We only measured what food was left in the tray, not food on the floor of the
cage, so there is sure to be a great deal of variability in our recordings. To
correct this issue in the future, food needs to be readily available to the animal in
a matter that we can insure the exact amount being eaten, for example; placing
food within a dish inside the cage itself.
In summary, 8 weeks of β-GPA feeding in ob/ob mice increases activation
of AMPK (p) T72 and its substrate ACC (p) T79 (Fig 2a). The efficacy of the
treatment is supported by the significant decrease in the levels of ATP within βGPA fed groups (Fig 2b). 8 weeks of β-GPA feeding in ob/ob mice also causes
dramatic decreases in body mass which is accompanied by slight increases in
skeletal muscle mass (Table 1). Therefore, β-GPA feeding is an effective means
by which to improve body composition in ob/ob mice.
Specific Aim 2:
Previous research in obese skeletal muscle has focused mostly on
understanding the metabolic state of the muscle, such as hyperinsulinemia,
hyperglycemia, insulin sensitivity, glucose disposal, dyslipidemia, and glycogen
metabolism (25, 28, 40, 58, 82, 88, 94, 96). In the current study we examined
several indicators of metabolic function within the skeletal muscle of obese mice.
The current data show that AMPK (p) T72 was elevated in ob/ob mice after 8
weeks of feeding with of β-GPA, which regulates glucose metabolism and
gluconeogenesis (66). The rate limiting enzyme in fatty acid oxidation, ACC (p)
T79 (83), was also elevated in the β-GPA fed ob/ob mice. This suggests that 8
weeks of β-GPA feeding in ob/ob mice increases the efficiency of energy
utilization within these animals. PGC-1α and COXIV are good indicators of
oxidative metabolism and mitochondrial function, respectively (11, 93). PGC-1α
increased significantly in the lean mice fed β-GPA but no changes were seen in
the ob/ob mice (Fig 5a). No statistical significant changes were seen in COXIV in
both groups (Fig 5b), however, there was a trend toward significance in both
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groups. Together, these data suggest that 8 weeks of β-GPA feeding improves
the metabolic function of skeletal muscle in ob/ob mice.
The increased potential for growth in ob/ob mice in the current study
comes from the changes in mTOR signaling as a result of β-GPA feeding.
Though no changes in raptor associated with mTOR were seen (Fig 7), there
were alterations in the downstream machinery of mTORC1 signaling. S6K1 (p)
T389 was reduced to levels equivalent to those of the lean control mice (Fig 8b).
S6K1 is used as an indicator of mTORC1 activity and is shown to be elevated in
ob/ob mice (54). Rivas et al. – 2009 showed that following a high fat diet, S6K1
was elevated by 20% at T389 and this increase was totally reversed following
exercise training (i.e. AMPK activation) (67).

Elevated S6K1 results in an

increase in IRS-1 phosphorylation through negative feedback; decreasing insulin
sensitivity and ultimately giving rise to insulin resistance in chronic situations
(67). In mice that are S6K1 deficient, there is a protective effect against obesity
and insulin resistance because of an upregulation in oxidative phosphorylation
and insulin sensitivity (90). Therefore, its lower activation seen after 8 weeks of
β-GPA in ob/ob mice in the current study is suggestive of more normalized
mTOR signaling and some protective effect against insulin resistance.
Interestingly, another mTORC1 substrate, 4E-BP1 (p), was significantly
increased in ob/ob mice fed β-GPA (Fig 9a). No statistical significance was seen
in total 4E-BP1. 4E-BP1 regulates 40S ribosome binding to mRNA by increasing
the availability of eIF-4E (78). When 4E-BP1 is phosphorylated it releases eIF4E allowing it to bind with eIF-4G and subsequently to the 40S ribosomal subunit
(78). A rise in 4E-BP1 was seen in our previous data after 2 weeks of injections
with the AMPK kinase activator AICAR. It is unclear at this time what role an
increase in 4E-BP1 after treatment with an AMPK kinase activator means. One
thought is that 4E-BP1 acts to protect against excessive fat deposition and
insulin resistance. Le Bacquer et al showed that in 4E-BP1 and 4E-BP2 double
knock out (DKO) mice gained significantly more body mass as well as fat mass
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than their wild type counterparts (46). When a high fat diet was fed to these DKO
mice, insulin resistance was promoted to a greater extent than in the wild type
mice (46).

It could be that the increase in 4E-BP1 that we observed is a

protective measure to guard against the ob/ob mice regaining the fat mass that
they had lost in regards to the β-GPA feeding. In DKO mice, S6K1
phosphorylation was significantly increased, suggesting that, though both are
downstream of mTORC1, and may have a role in influencing each other (46).
Our current data are supportive of this thought given the reciprocal changes in
4E-BP1 and S6K1 with β-GPA treatment.
We also examined 4E-BP1 within the eIF-4F complex in hopes of
determining what role it plays in obese skeletal muscle. No significant changes
occurred in eIF-4G or 4E-BP1 within the 4F complex following 8 weeks of feeding
with β-GPA in ob/ob mice (Fig 6). Though 4E-BP1 is phosphorylated by
mTORC1, it is not the only signaling pathway that influences 4E-BP1. Protein
kinase Cδ (PKCδ) and the MAP kinase pathway have also been shown to
phosphorylated 4E-BP1 (30, 45). Insulin has also been shown to regulate the
phosphorylation of 4E-BP1 through the phosphitidylinositol 3-kinase (PI 3-kinase)
signaling pathway, which is dependent on the phosphorylation and activation of
protein kinase B (PKB)/Akt (22, 80, 91). Had we analyzed skeletal muscle under
fed conditions, we may have observed lower 4E-BP1 in our eIF-4E IPs, providing
an alternative perspective to our treatment. However, determining the exact role
4E-BP1 plays in obese skeletal muscle remains unclear at this time.
The other binding component of mTOR, rictor, is rapamycin insensitive.
TORC2 controls the phosphorylation of PKB/Akt (70) that acts as a negative
feedback regulator of TORC1 activation (6). In the current data, there were no
significant changes in Akt found in ob/ob mice after 8 the week β-GPA feeding.
Rictor knock out (RImKO) mice function normally but display slight decreases in
the amount of raptor (4). In these RImKO mice Akt is still phosphorylated on Ser
473 so TORC2 is not solely responsible for Akt phosphorylation. Also, Akt is
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hypothesized to play a role in the degree of raptor expression (4). No change in
Akt in the current study could account for the lack of change seen in raptor’s
association with mTOR. However, the downstream target of Akt, GSK3β, which
inhibits glycogen synthase (33, 52), was significantly reduced in ob/ob mice after
β-GPA feeding. Since Akt was unchanged following β-GPA feeding in ob/ob
mice in the current study, there could be another controller of GSK3 activity.
S6K1 has been shown to regulate GSK3 upon the loss of TSC1-2 (99) in vitro,
but more works needs to be done to determine any association in vivo.
In future studies, we would propose to shorten the β-GPA feeding period
to 4-6 weeks, because weight loss in the ob/ob was the greatest at this time. To
add to those data we would analyze other pathways that are known to influence
4E-BP1 (Erk, PI-3 kinase, and/or PKCδ) in order to determine what is controlling
the increase observed in 4E-BP1 following β-GPA feeding. Moreover, examining
the muscles under fed conditions could provide insight into how a known insulin
resistant animal (ob/ob mouse) functions following β-GPA treatment, which would
give a more complete picture of translation initiation within obese skeletal
muscle. Given the normalization in skeletal muscle metabolism and growth
signaling seen in ob/ob mice after β-GPA feeding in the current data, we would
propose to subject these animals to an exercise regime or return them to a
normal diet following 4-6 weeks of β-GPA feeding and examine how they
respond to growth stimuli.
In summary, 8 weeks of β-GPA feeding caused decreases in body mass
in ob/ob mice, which was accompanied by a slight increase in skeletal muscle
mass. The obese mouse muscle was more metabolically active following β-GPA
feeding, evidenced by elevated AMPK (p) T72 and ACC (p) S79 levels. β-GPA
feeding did return certain downstream targets of mTORC 1 and 2 signaling
(S6K1 (p) T389 and GSK3) to a level that is comparative with that of their lean
counterparts, which exerts a potential protective effect against regaining fat
mass. Taken together, it is feasible that β-GPA feeding returns ob/ob skeletal
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muscle to a state in which growth can be attained under the proper stimulus (i.e.
exercise or nutrition), not unlike their lean counterparts.
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